Neratinib (INN), sold under the brand name Nerlynx, is a tyrosine kinase inhibitor anti-cancer medication used for the treatment of breast cancer. The...
16 KB (1,300 words) - 02:35, 16 July 2024
in 2010. In August 2011 Puma licensed two drug candidates from Pfizer: neratinib (PB272) and an analog (PB357) to serve as a backup candidate.: 6, 23 ...
9 KB (798 words) - 07:15, 29 February 2024
afatinib, axitinib, brigatinib, baricitinib, cabozantinib, dasatinib, neratinib, eltrombopag, ibrutinib, lenvatinib, palbociclib, regorafenib, tofacitinib...
5 KB (232 words) - 10:23, 8 March 2024
1-1% frequency) Keratitis Interstitial lung disease Like lapatinib and neratinib, afatinib is a protein kinase inhibitor that also irreversibly inhibits...
15 KB (1,122 words) - 15:16, 4 August 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
31 KB (3,430 words) - 05:24, 28 August 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
121 KB (13,799 words) - 18:31, 13 September 2024
anti-HER2 therapeutics are also tyrosine kinase inhibitors (Lapatinib, Neratinib, and Tucatinib) and antibody-drug conjugates (ado-trastuzumab emtansine...
43 KB (4,651 words) - 13:41, 27 July 2024
expected to lead to a wider therapeutic index. The pan-ErbB inhibitor Neratinib was approved in the US in 2017 and in the EU in 2018 for the extended...
20 KB (2,061 words) - 05:47, 29 November 2023
Neptazane nequinate (INN) neramexane mesylate (USAN) neraminol (INN) neratinib (USAN) nerbacadol (INN) nerelimomab (INN) neridronic acid (INN) nerisopam...
5 KB (316 words) - 04:07, 14 August 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
13 KB (1,177 words) - 02:19, 4 September 2024
margetuximab can also prolong survival, as can HER2 inhibitors lapatinib, neratinib, or tucatinib. Certain therapies are targeted at those whose tumors have...
132 KB (14,917 words) - 06:58, 13 September 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
92 KB (8,671 words) - 18:15, 17 August 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
16 KB (1,784 words) - 04:08, 6 January 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
73 KB (6,455 words) - 18:49, 12 September 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
149 KB (15,717 words) - 22:05, 8 September 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
7 KB (492 words) - 07:27, 13 September 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
10 KB (661 words) - 04:10, 26 June 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
20 KB (1,566 words) - 08:58, 12 August 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
46 KB (5,344 words) - 03:26, 11 August 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
21 KB (1,808 words) - 17:43, 7 September 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
29 KB (2,696 words) - 14:16, 27 July 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
40 KB (4,578 words) - 12:30, 10 September 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
16 KB (1,322 words) - 22:43, 12 September 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
17 KB (1,708 words) - 13:56, 21 July 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
27 KB (3,071 words) - 04:54, 3 June 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
16 KB (1,122 words) - 03:21, 24 April 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
105 KB (12,321 words) - 09:33, 9 September 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
24 KB (2,877 words) - 01:06, 8 September 2024
Canertinib Dacomitinib Erlotinib Gefitinib Grandinin Icotinib Lapatinib Neratinib Osimertinib Vandetanib WHI-P 154 Antibodies: Cetuximab Depatuxizumab Depatuxizumab...
19 KB (1,435 words) - 22:27, 16 June 2024
co-opted to promote cancer cell survival and metastasis. In breast cancers, neratinib, a novel pan-ERBB inhibitor, is able to downmodulate the amount of HER2...
64 KB (6,802 words) - 15:14, 22 August 2024